

theme that can be derived from our study and the study by Bikdeli et al. (2) is that the burden of infective endocarditis hospitalization rates in the United States is high and rising, which ultimately confers to higher health care expenditure and morbidity. Hence, a multispecialty collaborative effort is needed to understand the factors responsible and identify the strategies to halt this rising trend. We believe that the ongoing monitoring of the impact of the prophylaxis guidelines and appropriate updates on the basis of such data is an essential step in this regard.

Sadip Pant, MD  
Abhishek Deshmukh, MD  
Apurva Badheka, MD  
\*Jawahar L. Mehta, MD, PhD

\*Division of Cardiology  
University of Arkansas for Medical Sciences  
4301 West Markham Street  
Little Rock, Arkansas 72205  
E-mail: [MehtaJL@uams.edu](mailto:MehtaJL@uams.edu)  
<http://dx.doi.org/10.1016/j.jacc.2015.07.071>

Please note: The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

#### REFERENCES

1. Pant S, Patel NJ, Deshmukh A, et al. Trends in infective endocarditis incidence, microbiology, and valve replacement in the United States from 2000 to 2011. *J Am Coll Cardiol* 2015;65:2070-6.
2. Bikdeli B, Wang Y, Kim N, Desai MM, Quagliarello V, Krumholz HM. Trends in hospitalization rates and outcomes of endocarditis among Medicare beneficiaries. *J Am Coll Cardiol* 2013;62:2217-26.
3. Dayer M, Thornhill M. Antibiotic prophylaxis guidelines and infective endocarditis: cause for concern? *J Am Coll Cardiol* 2015;65:2077-8.

## How to Control Residual Risk During the Statin Era?



The Schwartz et al. (1) paper reported that among patients with acute coronary syndrome treated effectively with statins, fasting triglycerides (Tg) predict long-term and short-term cardiovascular risk. Triglyceride-rich lipoproteins may be an important additional target for therapy (1).

Lowering low-density lipoprotein cholesterol (LDL-C) is the primary target in the management of dyslipidemia in patients at high risk of cardiovascular disease. However, patients who have achieved LDL-C levels below the currently recommended targets may still experience cardiovascular events. This may result, in part, from elevated Tg levels (2). Atherogenic dyslipidemia, characterized by high Tg,

low levels of high-density lipoprotein cholesterol (HDL-C), and small, dense LDL particles, is a typical phenotype of dyslipidemia in subjects with insulin resistance and metabolic syndrome. On the other hand, raised Tg concentrations are strongly associated with low concentrations of HDL-C, and the past 15 years have been dominated by HDL research, with less focus on Tg. However, the understanding from genetic studies and randomized trials that low HDL-C might not be a cause of cardiovascular disease as originally thought has generated renewed interest in raised Tg (3). Indeed, a study investigated the causal role of HDL-C and Tg using multiple instrumental variables for Mendelian randomization and reported that the genetic findings supported a causal effect of Tg on coronary heart disease risk (4).

It is obvious that statins are the first-line drug for the treatment of dyslipidemia. However, a strategy to reduce high Tg and modify the small, dense LDL particles is required. In this regard, statin-based combined with fibrates, peroxisome proliferator-activated receptor agonists may be recommended in addition to therapeutic lifestyle changes if patients still experience cardiovascular events. The cost effectiveness of these combinations should also be evaluated (5).

\*Kwang Kon Koh, MD, PhD  
\*Vascular Medicine and Atherosclerosis Unit  
Department of Cardiovascular Medicine  
Gachon University  
Gil Medical Center  
774 Beongil 21  
Namdongdaero, Namdong-Gu, Incheon  
South Korea  
E-mail: [kwangk@gilhospital.com](mailto:kwangk@gilhospital.com)  
<http://dx.doi.org/10.1016/j.jacc.2015.07.072>

Please note: Dr. Koh has reported that he has no relationships relevant to the contents of this paper to disclose.

#### REFERENCES

1. Schwartz GG, Abt M, Bao W, et al. Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins. *J Am Coll Cardiol* 2015;65:2267-75.
2. Lim S, Park YM, Sakuma I, Koh KK. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. *Int J Cardiol* 2013; 166:8-14.
3. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet* 2014;384:626-35.
4. Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2014;36: 539-50.
5. Lim S, Oh PC, Sakuma I, Koh KK. How to balance cardiometabolic benefits and risks of statins. *Atherosclerosis* 2014;235:644-8.